3 hours ago
Replimune (REPL) Stock: Biotech Shares Surge 100% on Regulatory Breakthrough
TLDR FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline for the drug’s approval Replimune stock doubled on Monday, rising 100% to $9.00 per share in late-session trading The resubmission followed a complete response letter [...]
The post Replimune (REPL) Stock: Biotech Shares Surge 100% on Regulatory Breakthrough appeared first on Blockonomi.
Source: Blockonomi →Related News
- 2 hours ago
Best AI Stocks To Buy Today
- 2 hours ago
Cathie Wood Sells $3.7M Palantir While Adding to Qualcomm and Exact Sciences
- 2 hours ago
DocGo (DCGO) Stock Soars on SteadyMD Acquisition News
- 3 hours ago
Why is GSI Technology Stock Soaring Today?
- 3 hours ago
Amazon Cloud Outage Fixed After Worldwide Internet Services Impacted